CXADR, CXADR Ig-like cell adhesion molecule, 1525

N. diseases: 305; N. variants: 1
Disease: Glioblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 AlteredExpression disease BEFREE We then tested the antitumor activity of B7-H3-redirected CAR-T cells against GBM cell lines and patient-derived GBM neurospheres in vitro and in xenograft murine models. 31466914 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with <i>ex vivo</i> activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. 31798595 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 GeneticVariation disease BEFREE Our findings indicate that multiparametric MRI may be helpful in monitoring CAR-T related early therapeutic changes in GBM patients. 30478409 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE These results suggested that tumor-selective, bitargeted anti-EGFR/EGFRvIII CAR T cells may be a promising modality for the treatment of patients with EGFR/EGFRvIII-overexpressing glioblastoma.<i></i>. 30201736 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE A first-in man exploratory study evaluating EGFRvIII-specific CAR T cells for patients with newly diagnosed glioblastoma demonstrated overall safety of CAR T cell therapy and effective target recognition. 29666934 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE These studies identify a previously uncharacterized and ubiquitously expressed immunosuppressive ligand CD70 in GBMs that also holds potential for serving as a novel CAR target for cancer immunotherapy in gliomas. 28651374 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE Further, maintenance of the CD4+ subset was positively correlated with the recursive killing ability of CAR T cell products derived from GBM patients. 29769444 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 GeneticVariation disease BEFREE CSPG4 Shows Promise for Glioblastoma CAR T Therapy. 29540359 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE A single dose of peripherally infused CAR T cells cleared antigen-expressing tumor cells in patients with glioblastoma, a 10-person trial found. 28754782 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 GeneticVariation disease BEFREE Targeting Glioblastoma with CAR T Cells. 28108463 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated a satisfactory efficacy in treating malignant brain tumors. 28302023 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 Biomarker disease BEFREE We transduced human NK cell lines NK-92 and NKL, and primary NK cells with a lentiviral construct harboring a second generation CAR targeting both wtEGFR and EGFRvIII and evaluated the anti-GB efficacy of EGFR-CAR-modified NK cells. 26155832 2015
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.100 AlteredExpression disease BEFREE By flow cytometric analysis, H1299 (lung) and SW620 (colorectal) tumor cells showed high levels of CAR expression, whereas LN444 (glioblastoma), LNZ308 (glioblastoma), and H1299-R5 (lung) tumor cells were negative for CAR expression. 15735729 2005